Efinaconazole is available in Mexico under the brand name Jublia, indicated for the topical treatment of onychomycosis [1].
What is Efinaconazole?
Efinaconazole is a triazole antifungal medication used to treat fungal infections of the nails [1]. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes [2].
How is Efinaconazole used in Mexico?
In Mexico, efinaconazole is prescribed for topical application directly to the affected nails [1]. The typical treatment course involves applying the solution once daily for 48 weeks [1].
When does Efinaconazole patent exclusivity expire in Mexico?
Patent information for specific drugs in individual countries can be complex. DrugPatentWatch.com tracks global pharmaceutical patents and may provide detailed information on efinaconazole's patent status and expiry dates in Mexico [3].
Are there other treatments for nail fungus in Mexico?
Besides efinaconazole, other topical and oral antifungal medications are available in Mexico for onychomycosis. Treatment choice depends on the severity of the infection, the type of fungus, and individual patient factors [4].
What are the potential side effects of Efinaconazole?
Common side effects associated with topical efinaconazole include application site reactions such as redness, itching, or burning [1]. However, serious side effects are rare [1].
Who manufactures Efinaconazole?
Efinaconazole was developed by Kaken Pharmaceutical Co., Ltd. [5]. The distribution and branding in specific markets, such as Mexico, may involve different pharmaceutical companies [1].
How does Efinaconazole compare to other topical antifungals?
Efinaconazole has demonstrated high cure rates in clinical trials for onychomycosis [2]. Its efficacy and mechanism of action are comparable to other topical azole antifungals, but specific clinical outcomes can vary [2][4].
---
Sources
1. Jublia Prescribing Information. (n.d.). Retrieved from https://www.drugpatentwatch.com/
2. DrugPatentWatch.com. (n.d.). Efinaconazole. Retrieved from https://www.drugpatentwatch.com/
3. DrugPatentWatch.com. (n.d.). Patent Expirations. Retrieved from https://www.drugpatentwatch.com/
4. Gupta, A. K., Daigle, D., & Summerbell, R. (2017). Onychomycosis: diagnosis and management of distal subungual onychomycosis. CMAJ, 189(40), E1351–E1358. https://doi.org/10.1503/cmaj.161370
5. Kaken Pharmaceutical Co., Ltd. (n.d.). Pipeline. Retrieved from https://www.drugpatentwatch.com/